Who is sponsoring NCT04677049?

NCT04677049 is sponsored by AHS Cancer Control Alberta.

What drugs are being tested in NCT04677049?

Interventions in NCT04677049: Niacin CRT.

What condition does NCT04677049 study?

NCT04677049 studies Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype.

Is NCT04677049 still recruiting?

NCT04677049 is currently suspended. Last updated 2 January 2026.

Last reviewed 2026-01-02 · How we verify

NCT04677049

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Niacin in Glioblastoma

Suspended Phase 1, PHASE2 Last updated 2 January 2026

What this trial tests

Phase 1, PHASE2 trial testing Niacin CRT in Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype in 59 participants. Suspended.

Timeline

18 March 2021

Primary endpoint
31 December 2026

31 December 2026

Quick facts

Lead sponsor	AHS Cancer Control Alberta
Phase	Phase 1, PHASE2
Status	Suspended
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	59
Start date	18 March 2021
Primary completion	31 December 2026
Estimated completion	31 December 2026
Sites	1 location across Canada

Drugs / interventions tested

Niacin CRT — full drug profile →

Conditions studied

Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype — all drugs for Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype →

Sponsor

AHS Cancer Control Alberta — full company profile →

Who can join

Adults 18 to 75, any sex, with Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single institution Phase I-II study to evaluate the tolerability and Maximum Tolerated Dose (MTD) (Phase I) and efficacy (Phase II) of adding Niacin CRT™ to standard first line treatment (concurrent Radiation Therapy (RT) and Temozolomide (TMZ) following by monthly TMZ - AKA Stupp protocol) in patients with newly diagnosed glioblastoma isocitrate dehydrogenase (IDH) wild type.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

The niacin receptor HCAR2 modulates microglial response and limits disease progression in a mouse model of Alzheimer's disease.
Moutinho M, Puntambekar SS, Tsai AP, Coronel I, et al · · 2022 · cited 71× · PMID 35320002 · DOI 10.1126/scitranslmed.abl7634
The Promise of Niacin in Neurology.
Wuerch E, Urgoiti GR, Yong VW. · · 2023 · cited 38× · PMID 37084148 · DOI 10.1007/s13311-023-01376-2
A Perspective of Epigenetic Regulation in Radiotherapy.
Peng Q, Weng K, Li S, Xu R, et al · · 2021 · cited 28× · PMID 33681204 · DOI 10.3389/fcell.2021.624312
Next Steps for Immunotherapy in Glioblastoma.
Cao TQ, Wainwright DA, Lee-Chang C, Miska J, et al · · 2022 · cited 17× · PMID 36011015 · DOI 10.3390/cancers14164023
Structural basis of hydroxycarboxylic acid receptor signaling mechanisms through ligand binding.
Suzuki S, Tanaka K, Nishikawa K, Suzuki H, et al · · 2023 · cited 15× · PMID 37736747 · DOI 10.1038/s41467-023-41650-7
Structural insights into ligand recognition and selectivity of the human hydroxycarboxylic acid receptor HCAR2.
Pan X, Ye F, Ning P, Zhang Z, et al · · 2023 · cited 12× · PMID 38012147 · DOI 10.1038/s41421-023-00610-7
Daily Lifestyle Modifications to Improve Quality of Life and Survival in Glioblastoma: A Review.
Travers S, Litofsky NS. · · 2021 · cited 12× · PMID 33922443 · DOI 10.3390/brainsci11050533
Crosstalk of Epigenetic and Metabolic Signaling Underpinning Glioblastoma Pathogenesis.
Markouli M, Strepkos D, Papavassiliou KA, Papavassiliou AG, et al · · 2022 · cited 9× · PMID 35681635 · DOI 10.3390/cancers14112655

Verify or expand the search:

Other recruiting trials for Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype

Currently open trials in the same condition.

NCT05879367 — Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma · Phase 1 · recruiting

Other AHS Cancer Control Alberta trials

Trials by the same sponsor.

NCT05128734 — Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC) · Phase 2 · not yet recruiting
NCT06860542 — Inhaled Budesonide for REcurrence Prevention and Adjuvant THerapy in Checkpoint Inhibitor Pneumonitis · Phase 2 · recruiting
NCT05345847 — Steroid Sparing in Immune Related Hepatitis (irH) · NA · recruiting
NCT05407987 — Ferric Derisomaltose and Outcomes in the Recovery of Gynecologic Oncology: ERAS (Enhanced Recovery After Surgery) · Phase 3 · recruiting
NCT05421416 — Loratadine for the Prevention of G-CSF-related Bone Pain · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04677049 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AHS Cancer Control Alberta
Last refreshed: 2 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04677049.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing